Kazia Therapeutics Files Routine 6-K

Ticker: KZIA · Form: 6-K · Filed: Nov 4, 2024 · CIK: 1075880

Sentiment: neutral

Topics: sec-filing, 6-K, foreign-private-issuer

TL;DR

Kazia Therapeutics filed a 6-K, standard foreign issuer report, no new info.

AI Summary

Kazia Therapeutics Limited, based in Sydney, NSW, filed a Form 6-K on November 4, 2024. This report is for the month of November 2024 and indicates the company files annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for foreign private issuers.

Why It Matters

This filing is a standard disclosure for foreign private issuers, indicating ongoing compliance with SEC reporting requirements without providing new material information.

Risk Assessment

Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new material information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to submit information required by the laws of the foreign country of its domicile or incorporation, or that it makes or is required to make public pursuant to the laws of the foreign country of its domicile or incorporation.

Does this filing contain specific financial results for Kazia Therapeutics?

No, this Form 6-K filing does not appear to contain specific financial results or operational updates; it is a routine disclosure.

What is Kazia Therapeutics Limited's principal executive office address?

Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.

What is the SEC file number for Kazia Therapeutics?

The SEC file number for Kazia Therapeutics is 000-29962.

Does Kazia Therapeutics file annual reports under Form 20-F or 40-F?

Kazia Therapeutics indicates that it files annual reports under cover of Form 20-F.

Filing Stats: 288 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-11-04 16:33:55

Filing Documents

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On November 4, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is attached hereto as Exhibit 99.2. EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated November 4, 2024 99.2 Corporate Presentation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: November 4, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing